About Penumbra (NYSE:PEN)
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment
- Sub-Industry: N/A
- Symbol: NYSE:PEN
- CUSIP: N/A
- Web: www.penumbrainc.com
- Market Cap: $3.22 billion
- Outstanding Shares: 33,772,000
- 50 Day Moving Avg: $90.42
- 200 Day Moving Avg: $86.37
- 52 Week Range: $56.05 - $97.65
Sales & Book Value:
- Trailing P/E Ratio: 645.61
- Foreward P/E Ratio: 954.50
- P/E Growth: -70.28
- Annual Revenue: $294.09 million
- Price / Sales: 10.96
- Book Value: $11.04 per share
- Price / Book: 8.65
- EBITDA: ($3,320,000.00)
- Net Margins: -2.78%
- Return on Equity: -2.58%
- Return on Assets: -2.27%
- Current Ratio: 9.72%
- Quick Ratio: 7.56%
- Average Volume: 145,472 shs.
- Beta: 0.09
- Short Ratio: 17.55
Frequently Asked Questions for Penumbra (NYSE:PEN)
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra, Inc. (NYSE:PEN) posted its earnings results on Tuesday, August, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The firm had revenue of $80.60 million for the quarter, compared to analyst estimates of $77.16 million. Penumbra had a negative return on equity of 2.58% and a negative net margin of 2.78%. Penumbra's revenue was up 23.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 EPS. View Penumbra's Earnings History.
Where is Penumbra's stock going? Where will Penumbra's stock price be in 2017?
2 brokerages have issued 12 month target prices for Penumbra's stock. Their forecasts range from $96.00 to $100.00. On average, they expect Penumbra's stock price to reach $98.00 in the next twelve months. View Analyst Ratings for Penumbra.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include bluebird bio (BLUE), Bioverativ (BIVV), TESARO (TSRO), Icon Plc (ICLR), Dr. Reddy's Laboratories Ltd (RDY), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), Hill-Rom Holdings (HRC), United Therapeutics Corporation (UTHR), Envision Healthcare Corporation (EVHC), Neurocrine Biosciences (NBIX), PRA Health Sciences (PRAH), Galapagos NV (GLPG), athenahealth (ATHN), Juno Therapeutics (JUNO), Bio-Techne Corp (TECH), Masimo Corporation (MASI) and Medidata Solutions (MDSO).
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Adam Elsesser, Chairman of the Board, President, Chief Executive Officer
- Sridhar Kosaraju, Chief Financial Officer and Head of Strategy
- Daniel Donen Davis, President, North America
- James Pray, President, International
- Robert D. Evans, Executive Vice President, General Counsel, Secretary
- Lynn Rothman, Executive Vice President and Chief Business Officer
- Arani Bose M.D., Executive Director and Chief Innovator
- Harpreet S. Grewal, Independent Director
- Don W. Kassing, Presiding Independent Director
- Bridget O'Rourke, Independent Director
Who owns Penumbra stock?
Penumbra's stock is owned by a number of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.28%) and Strs Ohio (0.05%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Who bought Penumbra stock? Who is buying Penumbra stock?
How do I buy Penumbra stock?
Shares of Penumbra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
MarketBeat Community Rating for Penumbra (NYSE PEN)MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Penumbra stock can currently be purchased for approximately $95.45.
Earnings History for Penumbra (NYSE:PEN)Earnings History by Quarter for Penumbra (NYSE PEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.05)||($0.05)||$77.16 million||$80.60 million||View||Listen|
|5/9/2017||Q1 2017||($0.06)||($0.10)||$71.08 million||$73.21 million||View||Listen|
|2/28/2017||Q416||($0.09)||($0.08)||$67.54 million||$73.10 million||View||Listen|
|11/3/2016||Q316||($0.08)||($0.04)||$63.25 million||$67.20 million||View||N/A|
|8/9/2016||Q216||($0.07)||$0.01||$58.18 million||$65.10 million||View||N/A|
|5/9/2016||Q116||($0.07)||$0.02||$53.10 million||$57.90 million||View||N/A|
|3/8/2016||Q415||($0.10)||$0.05||$46.76 million||$54.40 million||View||N/A|
|11/12/2015||Q315||($0.15)||$0.03||$43.00 million||$50.42 million||View||N/A|
Earnings Estimates for Penumbra (NYSE:PEN)
Current Year EPS Consensus Estimate: $-0.21 EPS
Next Year EPS Consensus Estimate: $0.10 EPS
Dividend History for Penumbra (NYSE:PEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Penumbra (NYSE:PEN)
Insider Ownership Percentage: 13.50%Insider Trades by Quarter for Penumbra (NYSE:PEN)
Institutional Ownership Percentage: 70.93%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/5/2017||Harpreet Grewal||Director||Sell||500||$92.90||$46,450.00|| |
|10/2/2017||Thomas Wilder||Director||Sell||345||$90.20||$31,119.00|| |
|9/29/2017||Robert D Evans||EVP||Sell||20,017||$90.03||$1,802,130.51|| |
|9/28/2017||Robert D Evans||EVP||Sell||2,108||$90.00||$189,720.00|| |
|9/27/2017||Robert D Evans||EVP||Sell||1,586||$90.00||$142,740.00|| |
|9/21/2017||Robert D Evans||EVP||Sell||4,983||$90.00||$448,470.00|| |
|9/20/2017||Robert D Evans||EVP||Sell||2,859||$90.00||$257,310.00|| |
|8/21/2017||Harpreet Grewal||Director||Sell||4,500||$82.65||$371,925.00|| |
|8/9/2017||Robert D Evans||EVP||Sell||10,000||$85.15||$851,500.00|| |
|8/1/2017||Daniel Donen Davis||Insider||Sell||32,000||$79.42||$2,541,440.00|| |
|7/18/2017||Thomas Wilder||Director||Sell||345||$86.10||$29,704.50|| |
|4/24/2017||Robert D Evans||EVP||Sell||10,000||$85.24||$852,400.00|| |
|2/14/2017||Robert D Evans||EVP||Sell||5,000||$75.00||$375,000.00|| |
|2/13/2017||Adam Elsesser||CEO||Sell||7,700||$72.21||$556,017.00|| |
|2/13/2017||James Robert Pray||Insider||Sell||1,700||$73.04||$124,168.00|| |
|2/13/2017||Sridhar Kosaraju||CFO||Sell||1,600||$72.94||$116,704.00|| |
|2/10/2017||James Robert Pray||Insider||Sell||23,900||$71.08||$1,698,812.00|| |
|2/10/2017||Sridhar Kosaraju||CFO||Sell||15,500||$71.49||$1,108,095.00|| |
|2/9/2017||Arani Bose||Insider||Sell||22,300||$70.44||$1,570,812.00|| |
|2/9/2017||Lynn Rothman||EVP||Sell||2,700||$70.20||$189,540.00|| |
|2/7/2017||James Robert Pray||Insider||Sell||4,099||$69.09||$283,199.91|| |
|2/7/2017||Robert D Evans||EVP||Sell||1||$70.00||$70.00|| |
|2/6/2017||Arani Bose||Insider||Sell||17,100||$70.01||$1,197,171.00|| |
|2/6/2017||Lynn Rothman||EVP||Sell||2,886||$70.41||$203,203.26|| |
|2/6/2017||Sridhar Kosaraju||CFO||Sell||100||$70.00||$7,000.00|| |
|2/3/2017||James Robert Pray||Insider||Sell||15,600||$70.39||$1,098,084.00|| |
|2/3/2017||Robert D Evans||EVP||Sell||5,000||$70.35||$351,750.00|| |
|2/3/2017||Sridhar Kosaraju||CFO||Sell||7,800||$70.56||$550,368.00|| |
|2/1/2017||Adam Elsesser||CEO||Sell||21,400||$70.98||$1,518,972.00|| |
|2/1/2017||Daniel Donen Davis||Insider||Sell||7,298||$71.00||$518,158.00|| |
|2/1/2017||Lynn Rothman||EVP||Sell||4,414||$70.99||$313,349.86|| |
|1/31/2017||Adam Elsesser||CEO||Sell||9,000||$71.26||$641,340.00|| |
|1/31/2017||Daniel Donen Davis||Insider||Sell||3,000||$71.29||$213,870.00|| |
|1/31/2017||Lynn Rothman||EVP||Sell||1,800||$71.27||$128,286.00|| |
|1/30/2017||Adam Elsesser||CEO||Sell||8,200||$70.72||$579,904.00|| |
|1/30/2017||Daniel Donen Davis||Insider||Sell||2,698||$70.71||$190,775.58|| |
|1/30/2017||Lynn Rothman||EVP||Sell||1,700||$70.79||$120,343.00|| |
|1/27/2017||Arani Bose||Insider||Sell||31,500||$74.12||$2,334,780.00|| |
|1/27/2017||Lynn Rothman||EVP||Sell||7,000||$74.24||$519,680.00|| |
|1/26/2017||Don W Kassing||Director||Sell||3,000||$74.50||$223,500.00|| |
|11/16/2016||Sridhar Kosaraju||CFO||Sell||25,000||$65.07||$1,626,750.00|| |
|9/9/2016||Adam Elsesser||CEO||Sell||57,200||$71.07||$4,065,204.00|| |
|9/6/2016||Arani Bose||Insider||Sell||61,000||$70.72||$4,313,920.00|| |
|9/2/2016||Robert D Evans||EVP||Sell||3,100||$70.10||$217,310.00|| |
|8/31/2016||Adam Elsesser||CEO||Sell||26,000||$71.15||$1,849,900.00|| |
|8/31/2016||Robert D Evans||EVP||Sell||5,300||$71.17||$377,201.00|| |
|8/26/2016||Adam Elsesser||CEO||Sell||26,800||$71.06||$1,904,408.00|| |
|8/26/2016||Robert D Evans||EVP||Sell||5,300||$71.03||$376,459.00|| |
|8/24/2016||Adam Elsesser||CEO||Sell||29,000||$72.95||$2,115,550.00|| |
|8/24/2016||Robert D Evans||EVP||Sell||6,300||$73.00||$459,900.00|| |
|5/23/2016||Robert D Evans||EVP||Sell||5,000||$50.52||$252,600.00|| |
|5/19/2016||Don W Kassing||Director||Sell||3,000||$48.63||$145,890.00|| |
|5/19/2016||Robert D Evans||EVP||Buy||1,538||$25.50||$39,219.00|| |
|5/16/2016||James Robert Pray||Insider||Sell||32,500||$48.51||$1,576,575.00|| |
Headline Trends for Penumbra (NYSE:PEN)
Latest Headlines for Penumbra (NYSE:PEN)
Loading headlines, please wait.
Penumbra (PEN) Chart for Monday, October, 23, 2017